Your browser doesn't support javascript.
loading
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
McQuade, Jennifer L; Daniel, Carrie R; Hess, Kenneth R; Mak, Carmen; Wang, Daniel Y; Rai, Rajat R; Park, John J; Haydu, Lauren E; Spencer, Christine; Wongchenko, Matthew; Lane, Stephen; Lee, Dung-Yang; Kaper, Mathilde; McKean, Meredith; Beckermann, Kathryn E; Rubinstein, Samuel M; Rooney, Isabelle; Musib, Luna; Budha, Nageshwar; Hsu, Jessie; Nowicki, Theodore S; Avila, Alexandre; Haas, Tomas; Puligandla, Maneka; Lee, Sandra; Fang, Shenying; Wargo, Jennifer A; Gershenwald, Jeffrey E; Lee, Jeffrey E; Hwu, Patrick; Chapman, Paul B; Sosman, Jeffrey A; Schadendorf, Dirk; Grob, Jean-Jacques; Flaherty, Keith T; Walker, Dana; Yan, Yibing; McKenna, Edward; Legos, Jeffrey J; Carlino, Matteo S; Ribas, Antoni; Kirkwood, John M; Long, Georgina V; Johnson, Douglas B; Menzies, Alexander M; Davies, Michael A.
Afiliación
  • McQuade JL; University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jmcquade@mdanderson.org.
  • Daniel CR; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hess KR; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mak C; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Wang DY; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Rai RR; Melanoma Institute Australia and University of Sydney, North Sydney, NSW, Australia.
  • Park JJ; Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead NSW, Australia.
  • Haydu LE; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Spencer C; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wongchenko M; Genentech, San Francisco, CA, USA.
  • Lane S; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Lee DY; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Kaper M; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • McKean M; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Beckermann KE; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Rubinstein SM; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Rooney I; Genentech, San Francisco, CA, USA.
  • Musib L; Genentech, San Francisco, CA, USA.
  • Budha N; Genentech, San Francisco, CA, USA.
  • Hsu J; Genentech, San Francisco, CA, USA.
  • Nowicki TS; University of California Los Angeles Medical Center, Los Angeles, CA, USA.
  • Avila A; Bristol-Myers Squibb, New York, NY, USA.
  • Haas T; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Puligandla M; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lee S; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Fang S; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wargo JA; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gershenwald JE; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee JE; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hwu P; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chapman PB; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sosman JA; Northwestern University, Chicago, IL, USA.
  • Schadendorf D; University Hospital Essen and German Cancer Consortium, Essen, Germany.
  • Grob JJ; Centre Hospitalo-Universitaire Timone, Aix Marseille University, Marseille, France.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Walker D; Bristol-Myers Squibb, New York, NY, USA.
  • Yan Y; Genentech, San Francisco, CA, USA.
  • McKenna E; Genentech, San Francisco, CA, USA.
  • Legos JJ; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Carlino MS; Melanoma Institute Australia and University of Sydney, North Sydney, NSW, Australia; Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead NSW, Australia.
  • Ribas A; University of California Los Angeles Medical Center, Los Angeles, CA, USA.
  • Kirkwood JM; Hillman University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA, USA.
  • Long GV; Melanoma Institute Australia and University of Sydney, North Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, St Leonards, NSW, Australia.
  • Johnson DB; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Menzies AM; Melanoma Institute Australia and University of Sydney, North Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, St Leonards, NSW, Australia.
  • Davies MA; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lancet Oncol ; 19(3): 310-322, 2018 03.
Article en En | MEDLINE | ID: mdl-29449192
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Protocolos de Quimioterapia Combinada Antineoplásica / Índice de Masa Corporal / Terapia Molecular Dirigida / Antineoplásicos Inmunológicos / Melanoma / Obesidad Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Protocolos de Quimioterapia Combinada Antineoplásica / Índice de Masa Corporal / Terapia Molecular Dirigida / Antineoplásicos Inmunológicos / Melanoma / Obesidad Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article